alemtuzumab
Showing 1 - 25 of 145
Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)
Not yet recruiting
- Allogeneic Hematopoietic Cell Transplantation
- Alemtuzumab
- (no location specified)
Aug 12, 2022
T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)
Completed
- T-cell-prolymphocytic Leukemia
- Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
- Alemtuzumab
-
Cologne, GermanyUniversity Hospital Cologne
Dec 16, 2021
Chronic Granulomatous Disease Trial run by the NIAID (Sirolimus, Cyclophosphamide, Alemtuzumab)
Recruiting
- Chronic Granulomatous Disease
- Sirolimus
- +7 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 23, 2022
Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 2, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,
Terminated
- Relapsing-Remitting Multiple Sclerosis
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Hamburg, Germany
- +1 more
Mar 1, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- Bendamustine
- Alemtuzumab
-
Innsbruck, Tirol, Austria
- +6 more
Feb 15, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Münster (Alemtuzumab)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- Alemtuzumab
-
Münster, GermanyUniversitätsklinikum Münster, Klinik für Allgemeine Neurologie
Oct 25, 2021
Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)
Recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jul 31, 2022
Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)
Active, not recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Hackensack, New JerseyHackensack University Medical Center
Feb 4, 2022
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023
Sickle Cell Anemia Trial run by the NHLBI (PBSC Transplant, Alemtuzumab, Sirolimus)
Active, not recruiting
- Sickle Cell Anemia
- PBSC Transplant
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022
Secondary Malignant Tumor of Retroperitoneum, Secondary Malignant Tumor of Peritoneum, Pseudomyxoma Peritonei Trial in Cleveland
Not yet recruiting
- Secondary Malignant Neoplasm of Retroperitoneum
- +2 more
- Intestinal, Multivisceral or Modified Multivisceral Transplantation
- +3 more
-
Cleveland, OhioCleveland Clinic Digestive Disease & Surgery Institute (DDSI), C
Oct 10, 2023
Neurofilaments for NEDA Assessing in MS
Terminated
- Multiple Sclerosis
- Alemtuzumab
-
London, England, United KingdomQueen Mary University of London
Feb 9, 2022
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia Trial
Completed
- Acute Undifferentiated Leukemia
- +13 more
- allopurinol
- +16 more
-
Chicago, IllinoisCancer and Leukemia Group B
Apr 5, 2022
Chronic Granulomatous Disease Transplant Trial run by the NIAID (drug, radiation, biological)
Active, not recruiting
- Chronic Granulomatous Disease Transplant
- Alemtuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 21, 2023
Sickle Cell Anemia, Beta Thalassemia Trial run by the NHLBI (radiation, drug, biological)
Recruiting
- Sickle Cell Anemia
- Beta Thalassemia
- TBI
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Congenital Hemolytic Anemia, Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Peripheral
Recruiting
- Congenital Hemolytic Anemia
- Sickle Cell Disease
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Hemophagocytic Lymphohistiocytosis (HLH) Trial in Paris (Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA))
Completed
- Hemophagocytic Lymphohistiocytosis (HLH)
- Alemtuzumab
- +2 more
-
Paris, FranceHôpital Necker-Enfants Malades
Apr 13, 2021
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases Trial run by the NCI (drug, radiation,
Recruiting
- Lymphoproliferative Disorders
- +4 more
- Busulfan test dose
- +8 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Sickle Cell Disease Trial in Saint Louis (drug, radiation, procedure)
Terminated
- Sickle Cell Disease
- Alemtuzumab
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 28, 2022
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,
Recruiting
- Primary Immune Deficiency Disorder
- +2 more
- Alemtuzumab
- +6 more
-
Baltimore, MarylandJohns Hopkins University
Oct 20, 2022
Renal Transplantation Trial in United States (Alemtuzumab, rabbit antithymocyte globulin, Belatacept)
Completed
- Renal Transplantation
- Alemtuzumab
- +5 more
-
San Francisco, California
- +7 more
Jul 8, 2021